miR-183-5p Aggravates Breast Cancer Development via Mediation of RGS2.
Journal
Computational and mathematical methods in medicine
ISSN: 1748-6718
Titre abrégé: Comput Math Methods Med
Pays: United States
ID NLM: 101277751
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
08
2021
accepted:
09
10
2021
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
11
2
2022
Statut:
epublish
Résumé
This study mainly explores how miR-183-5p pertains to breast cancer (BC) development. Functional assays were employed to test impacts of miR-183-5p in this cancer. Targeting between RGS2 and miR-183-5p was examined with dual-luciferase assay, and how their interaction pertains to cancer progression was further unraveled. miR-183-5p level was noticeably high in cancer tissue/cells. Overexpressing miR-183-5p could remarkably deteriorate cancer progression. The regulatory gene RGS2 levels was markedly low in BC, and two genes we researched were negatively correlated. It was uncovered by rescue assay that miR-183-5p/RGS2 axis mediated tumor-relevant behaviors in BC. Altogether, miR-183-5p aggravates BC development via mediation of RGS2. miR-183-5p supplies a promising target for BC therapy.
Identifiants
pubmed: 34849149
doi: 10.1155/2021/9664195
pmc: PMC8627563
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN183 microRNA, human
0
MicroRNAs
0
RGS Proteins
0
RGS2 protein, human
0
RNA, Messenger
0
Types de publication
Journal Article
Retracted Publication
Langues
eng
Sous-ensembles de citation
IM
Pagination
9664195Commentaires et corrections
Type : RetractionIn
Informations de copyright
Copyright © 2021 Chihua Wu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no potential conflicts of interest.
Références
Nat Rev Drug Discov. 2010 Oct;9(10):775-89
pubmed: 20885409
J Clin Invest. 2007 Nov;117(11):3155-63
pubmed: 17975657
Biomed Pharmacother. 2019 Mar;111:1103-1111
pubmed: 30841423
Mol Cell. 2013 May 9;50(3):356-67
pubmed: 23603119
J Cell Biochem. 2015 Feb;116(2):260-7
pubmed: 25187114
Tumour Biol. 2015 Sep;36(10):8121-6
pubmed: 25983004
Oncogene. 2006 Jun 22;25(26):3719-34
pubmed: 16449965
Oncogene. 2016 Jan 14;35(2):173-86
pubmed: 25798833
Oncol Lett. 2018 Apr;15(4):5056-5070
pubmed: 29616090
Front Mol Biosci. 2021 Aug 19;8:697457
pubmed: 34490348
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Zhonghua Zhong Liu Za Zhi. 2020 Mar 23;42(3):161-169
pubmed: 32252194
Med Sci Monit. 2018 Oct 07;24:7137-7145
pubmed: 30293085
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Tumour Biol. 2015 Dec;36(12):9245-9
pubmed: 26091793
Cancer Radiother. 2020 Oct;24(6-7):482-492
pubmed: 32839105
PLoS One. 2014 May 02;9(5):e96228
pubmed: 24788655
Exp Cell Res. 2019 Jan 15;374(2):315-322
pubmed: 30528264
Indian J Clin Biochem. 2019 Apr;34(2):207-212
pubmed: 31092995
Oncol Lett. 2016 Jan;11(1):134-140
pubmed: 26870180
Int J Oncol. 2017 Apr;50(4):1097-1108
pubmed: 28350089
J Biol Chem. 2011 Dec 30;286(52):44503-11
pubmed: 22045813
Reprod Biol. 2016 Sep;16(3):225-233
pubmed: 27476679